Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Meng Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8807-5001; OpenAlex author ID A5019613537. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2014: 1 paper · 2015: 4 papers · 2016: 3 papers · 2017: 7 papers · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 21

  1. Growth differentiation factor-15 may be a novel biomarker in pancreatic cancer: A review. Co-author DOI 10.1097/md.0000000000036594↗
  2. Autologous ex vivo expanded NK cells combined with PD-1 inhibitor improved ascitic fluid immune microenvironment of peritoneal metastatic pancreatic cancer: a … Co-author PMID 36777837↗
  3. Large-Section Histopathology Can Better Indicate the Immune Microenvironment and Predict the Prognosis of Pancreatic Ductal Adenocarcinoma Than Small-Section H… First author DOI 10.3389/fonc.2021.694933↗
  4. Progress in Animal Models of Pancreatic Ductal Adenocarcinoma. First author DOI 10.7150/jca.37529↗
  5. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.08.003↗
  6. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001073↗
  7. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. Co-author DOI 10.1002/ijc.30650↗
  8. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. Co-author DOI 10.1016/j.canlet.2016.10.046↗
  9. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cance… Co-author DOI 10.1016/j.ejso.2017.07.010↗
  10. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000001741↗
  11. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5579-3↗
  12. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. Co-author DOI 10.3892/ijo.2017.4032↗
  13. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Co-author DOI 10.3892/ol.2016.5501↗
  14. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Co-author DOI 10.1016/j.pan.2016.09.007↗
  15. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. First author DOI 10.1016/j.pan.2016.09.013↗
  16. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. Co-author DOI 10.3390/ijms17071090↗
  17. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.03.012↗
  18. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. First author DOI 10.1245/s10434-014-4021-y↗
  19. Pancreatic cancer: BRCA mutation and personalized treatment. Co-author DOI 10.1586/14737140.2015.1086271↗
  20. U0126 inhibits pancreatic cancer progression via the KRAS signaling pathway in a zebrafish xenotransplantation model. Co-author DOI 10.3892/or.2015.4019↗
  21. Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Co-author DOI 10.1016/j.canlet.2014.01.004↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 16 shared papers, 2014–2018 · strength 0.94
  2. Guopei Luo · 16 shared papers, 2014–2018 · strength 0.94
  3. Chen Liu · 15 shared papers, 2014–2018 · strength 0.87
  4. Kaizhou Jin · 14 shared papers, 2015–2018 · strength 0.83
  5. Quanxing Ni · 13 shared papers, 2015–2018 · strength 0.78
  6. Jiang Long · 12 shared papers, 2014–2018 · strength 0.69
  7. Jin Xu · 11 shared papers, 2014–2018 · strength 0.61
  8. Liang Liu · 10 shared papers, 2014–2018 · strength 0.54
  9. He Cheng · 8 shared papers, 2016–2018 · strength 0.49
  10. Yanfang Liu · 3 shared papers, 2020–2023 · strength 0.47
  11. Hui Zhao · 1 shared paper, 2024 · strength 0.46
  12. Zuqiang Liu · 7 shared papers, 2015–2017 · strength 0.39
  13. Jianming Zheng · 2 shared papers, 2020–2021 · strength 0.29
  14. Zhiwen Xiao · 4 shared papers, 2015–2017 · strength 0.22
  15. Cheng He · 3 shared papers, 2015–2017 · strength 0.18
  16. Xiaobo Peng · 1 shared paper, 2023 · strength 0.18
  17. Ling Chen · 1 shared paper, 2023 · strength 0.18
  18. Xianbao Zhan · 1 shared paper, 2023 · strength 0.18
  19. Kaiwen Kong · 1 shared paper, 2020 · strength 0.16
  20. Chao Yang · 2 shared papers, 2018 · strength 0.14
  21. Guiling Ding · 1 shared paper, 2021 · strength 0.13
  22. Jiang Long · 2 shared papers, 2015 · strength 0.11
  23. C Liu · 1 shared paper, 2017 · strength 0.07
  24. Chunyan Yang · 1 shared paper, 2017 · strength 0.07
  25. Liang Liu · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.